OPEN END TURBO LONG - FRESENIUS MEDICAL CARE Share Price

Certificat

DE000MA3X3K2

Real-time Bid/Ask 01:28:04 20/06/2024 pm IST
0.95 EUR / 0.96 EUR +4.95% Intraday chart for OPEN END TURBO LONG - FRESENIUS MEDICAL CARE
Current month-25.41%
1 month-31.58%
Date Price Change
20/24/20 0.93 +2.20%
19/24/19 0.91 -5.21%
18/24/18 0.96 -4.95%
17/24/17 1.01 -12.17%
14/24/14 1.15 -1.71%

Delayed Quote Börse Stuttgart

Last update June 20, 2024 at 12:54 pm IST

More quotes

Static data

Product typeCertificat Turbo
Buy / SellCALL
Underlying FRESENIUS MEDICAL CARE AG
Issuer Morgan Stanley
WKN MA3X3K
ISINDE000MA3X3K2
Date issued 15/12/2020
Strike 27.05
Maturity Unlimited
Parity 10 : 1
Emission price 4.18
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 4.57
Lowest since issue 0.106
Spread 0.01
Spread %1.06%

Company Profile

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based Company, which is a kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Sector
-
More about the company

Ratings for Fresenius Medical Care AG

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Fresenius Medical Care AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
36.26 EUR
Average target price
39.97 EUR
Spread / Average Target
+10.24%
Consensus